SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of a Technology ...

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the establishment of the GeoMx ...

Premier Access Sites to Offer the Cancer Transcriptome Atlas Service from Labs Across the Globe SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life ...

Data in Twenty-One Poster and Oral Presentations Highlight use of GeoMx Digital Spatial Profiler and the Spatial Molecular Imager Platform for Discovery and Translational Applications During the 2021 ...

SEATTLE, April 30, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced ...

NanoString is accelerating the development of the Digital Spatial Profiling technology with customers via its Technology Access Program. Under the program, customers submit up to 20 FFPE tissue ...

SEATTLE, Wash. – November 18, 2009 – NanoString Technologies, Inc., a privately held life sciences company marketing a molecular barcoding detection system, today announced that it is collaborating ...

BOSTON and SEATTLE – Oct. 6, 2014 –NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that it ...

Good afternoon. My name is Krista and I'll be your conference operator today. At this time, I would like to welcome everyone to the NanoString Third Quarter Operating Results. All lines have been ...

Joe Beechem, PhD, CSO and senior vice president of research and development at NanoString Technologies is no stranger to the development of new genomic technologies. Moving from a substantial academic ...

Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.